KPIs & Operating Metrics(New)
Biologics And Drug Delivery Revenue By CategoryBiologics And Drug Delivery Revenue By Category AnnualBreakdown Of AssetsCapital Equipment And Software Revenue By CategoryCapital Equipment And Software Revenue By Category AnnualCost Of RevenueDeferred RevenueEmployee StatisticsFunctional Neurosurgery Navigation And Therapy Revenue By CategoryFunctional Neurosurgery Navigation And Therapy Revenue By Category AnnualGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Service LineRevenue By Service Line %Revenue By Service Line AnnualRevenue By Service Line Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Cost Of Revenue (2011 - 2026)

ClearPoint Neuro recorded quarterly Cost of Revenue of $4.4 million in Q1 2026, up 9.14% quarter-over-quarter from $4.0 million in Q4 2025, and up 30.39% year-over-year from $3.4 million in Q1 2025.

ClearPoint Neuro's Cost of Revenue history runs 15 years deep, the most recent figure standing at $4.4 million for Q1 2026.

  • In Q1 2026, Cost of Revenue rose 30.39% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $15.3 million (down 4.12% YoY), while the FY2025 annual figure was $14.3 million, down 1.37% from the prior year.
  • Cost of Revenue came in at $4.4 million for Q1 2026 at ClearPoint Neuro, up from $4.0 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $5.2 million in Q4 2024 to a low of $194000.0 in Q4 2022.
  • A 5-year average of $3.1 million and a median of $3.3 million in 2025 frame the typical range for Cost of Revenue.
  • Across the five-year window, Cost of Revenue tumbled 82.33% in 2022 and soared 1341.75% in 2023, its largest moves.
  • ClearPoint Neuro's Cost of Revenue stood at $194000.0 in 2022, then jumped by 1341.75% to $2.8 million in 2023, then jumped by 86.59% to $5.2 million in 2024, then retreated by 23.24% to $4.0 million in 2025, then increased by 9.14% to $4.4 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods registered $4.4 million, $4.0 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.